The topic of coexisting aortic stenosis (AS) and cardiac amyloidosis (CA) has become a classic of contemporary cardiology due to the spread of transcatheter aortic valve replacement (TAVR) as a treatment for AS and the wide availability of bone scintigraphy as a non-invasive diagnostic standard for transthyretin-related amyloidosis (ATTR).

Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle?

Rapezzi C.
Primo
;
Campo G.
Ultimo
2021

Abstract

The topic of coexisting aortic stenosis (AS) and cardiac amyloidosis (CA) has become a classic of contemporary cardiology due to the spread of transcatheter aortic valve replacement (TAVR) as a treatment for AS and the wide availability of bone scintigraphy as a non-invasive diagnostic standard for transthyretin-related amyloidosis (ATTR).
2021
Rapezzi, C.; Giannini, F.; Campo, G.
File in questo prodotto:
File Dimensione Formato  
European J of Heart Fail - 2020 - Rapezzi.pdf

solo gestori archivio

Descrizione: versione editoriale
Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 503.78 kB
Formato Adobe PDF
503.78 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2472159
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 5
social impact